Potential Attending Questions on Decompensated Heart Failure
1. Clinical Presentation & Initial Assessment
Q: What is this patient's hemodynamic profile?
Classify the patient as "wet vs dry" (congestion status) and "warm vs cold" (perfusion status). 1, 2 Over 80% of admitted HF patients are "wet and warm" (congested without hypoperfusion). Look specifically for:
- Congestion markers: Elevated jugular venous pressure (most sensitive sign), orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, hepatomegaly, ascites 1, 3
- Hypoperfusion markers: Narrow pulse pressure (<25% of systolic BP), cool extremities, oliguria, altered mental status, elevated lactate 3, 4
Critical pitfall: Rales may be absent in chronic HF despite severe congestion due to lymphatic compensation. 3 JVP is more reliable than lung findings.
Q: What precipitated this decompensation?
Identify the specific trigger—it's present in most cases and guides therapy. 1, 2, 5 The most common precipitants are:
Cardiovascular triggers:
- Acute coronary syndrome (obtain troponin and ECG immediately) 1
- Uncontrolled hypertension (present in ~50% of admissions) 2
- Atrial fibrillation/arrhythmias (present in >30% of acute HF) 2
- Recent addition of negative inotropes (verapamil, diltiazem, beta-blockers) 1, 5
Non-cardiovascular triggers:
- Medication/dietary non-adherence (leading cause) 1, 2, 4
- Infection (pneumonia, UTI—increases metabolic demand and may cause hypoxia) 2
- NSAIDs, steroids, thiazolidinediones (cause sodium retention) 2, 5
- Renal dysfunction 1, 2
- Thyroid abnormalities (check TSH, especially if on amiodarone) 2, 5
- Pulmonary embolism 1, 5
- Excessive alcohol or illicit drugs (cocaine, methamphetamine) 2, 5
2. Diagnostic Workup
Q: What initial tests are mandatory?
The diagnosis is clinical, but these tests are essential for assessment and risk stratification: 1
Immediate tests:
- ECG (ischemia, arrhythmias) 1
- Troponin (rule out ACS as precipitant) 1
- BNP or NT-proBNP (BNP >100 pg/mL or NT-proBNP >300 pg/mL supports HF diagnosis, but has lower sensitivity in obesity and HFpEF; may be normal in "flash" pulmonary edema) 1, 6
- Chest X-ray (pulmonary edema, pleural effusions, cardiomegaly) 1, 6
- Basic metabolic panel (renal function, electrolytes) 6
- Complete blood count (anemia as precipitant) 1
- Arterial blood gas if severe (assess oxygenation, acid-base status) 6
Within 24-48 hours:
- Echocardiography (assess EF, regional wall motion, valvular disease, RV function, pericardial disease) 1, 6
Q: What does the BNP tell you and what are its limitations?
BNP has excellent negative predictive value to exclude HF but requires clinical context. 1, 6
Limitations:
- Decreased sensitivity in obesity and HFpEF 4
- May remain normal during "flash" pulmonary edema 6
- Elevated in renal failure, sepsis, pulmonary embolism (decreased specificity) 6
- Higher baseline levels in elderly patients 6
Use BNP to support—not replace—clinical diagnosis. Elevated levels also provide prognostic information (higher levels = worse outcomes). 3, 6
3. Physical Examination Findings
Q: Walk me through your cardiovascular exam findings.
Describe these specific findings systematically:
Volume status assessment:
- JVP elevation (>8 cm H2O)—most sensitive sign of elevated filling pressures 3, 6
- Hepatojugular reflux
- Peripheral edema (grade and distribution)
- Ascites, hepatomegaly 3
Perfusion assessment:
- Pulse pressure (narrow <25% suggests low output) 3, 4
- Extremity temperature and capillary refill 3
- Mental status 3
Cardiac findings:
- S3 gallop (ventricular filling, indicates volume overload) 6
- S4 gallop (atrial contraction against stiff ventricle) 6
- Murmurs (mitral regurgitation, aortic stenosis) 6
- Displaced/sustained apical impulse 6
Pulmonary findings:
4. Immediate Management
Q: What are your first interventions in the emergency department?
Begin treatment immediately—early intervention improves outcomes: 1
For "wet and warm" patients (>80% of cases):
- Oxygen therapy if hypoxemic (target SpO2 >90%) 1
- IV loop diuretics within 30 minutes of presentation 1, 2
- Consider IV vasodilators (nitroglycerin, nitroprusside, nesiritide) if SBP >90 mmHg and severe congestion 5, 7
For "cold and wet" patients (hypoperfusion + congestion):
- Reduce negative inotropes if possible 2
- Consider inotropes (dobutamine 2-5 µg/kg/min or milrinone) if documented severe systolic dysfunction with low cardiac output 5, 7
- May require invasive hemodynamic monitoring 5
For severe hypertension with pulmonary edema:
- Aggressive IV vasodilators to reduce afterload 2
- Non-invasive positive pressure ventilation (BiPAP/CPAP) 7
Q: How do you dose diuretics in acute decompensated HF?
Use IV loop diuretics at doses equal to or exceeding the patient's home oral dose. 1
Dosing strategy:
- Initial bolus: 2.5× home oral dose IV, or 40-80 mg IV if diuretic-naive 1, 7
- If inadequate response: increase dose or add thiazide diuretic 2
- Consider continuous infusion for refractory cases 1
- Low-dose dopamine (2-5 µg/kg/min) may improve diuresis and preserve renal function 2
Monitor: Urine output (goal >1-2 L/day initially), daily weights, electrolytes, renal function 1
5. Guideline-Directed Medical Therapy (GDMT)
Q: Should I continue the patient's home HF medications during acute decompensation?
Yes—continue GDMT unless hemodynamically unstable or specific contraindications exist. 2, 4 This is a Class I recommendation.
Specifically:
- ACE inhibitors/ARBs/ARNI: Continue unless hypotensive or acute kidney injury 2, 4
- Beta-blockers: Continue at current dose unless cardiogenic shock or requiring inotropes 2, 4
- Mineralocorticoid receptor antagonists: Continue unless hyperkalemia or severe renal dysfunction 4
Do NOT routinely discontinue GDMT for:
Critical point: Discontinuing GDMT during hospitalization is associated with worse outcomes. 2, 4
Q: When do I initiate or uptitrate GDMT during hospitalization?
Initiate or uptitrate GDMT after clinical stability is achieved—before discharge. 2, 4
Timing for beta-blockers:
- Initiate only after: volume optimization, successful discontinuation of IV diuretics/vasodilators/inotropes 2
- Start at low dose in stable patients 2
- Use extreme caution if patient required inotropes 2
Timing for other GDMT:
- ACE-I/ARB/ARNI, MRA: Can be initiated or uptitrated once diuresis is effective and patient is clinically stable 4
- SGLT2 inhibitors: Emerging data supports initiation during hospitalization for HFrEF 4
Goal: Optimize GDMT before discharge to improve post-discharge trajectory. 3, 4
6. Inotropic Support
Q: When are inotropes indicated?
Inotropes are indicated ONLY for documented severe systolic dysfunction with low cardiac output and evidence of hypoperfusion (cardiogenic shock). 5 This is a Class IIb recommendation.
Specific indications:
- SBP <90 mmHg with signs of hypoperfusion (cool extremities, altered mental status, oliguria, elevated lactate) 5, 7
- Documented low cardiac output on hemodynamic monitoring 5
- End-organ dysfunction from hypoperfusion 5
Inotrope options:
- Dobutamine 2-5 µg/kg/min 5, 7
- Milrinone 0.375-0.75 µg/kg/min (avoid if renal dysfunction) 7
- Dopamine (less preferred due to arrhythmia risk) 2
Class III (DO NOT USE): Routine use of inotropes in normotensive patients without hypoperfusion is NOT recommended—associated with increased mortality. 5
7. Invasive Hemodynamic Monitoring
Q: When do you place a pulmonary artery catheter?
Consider PA catheter for carefully selected patients with persistent symptoms despite empiric therapy when: 5
- Fluid status or perfusion is uncertain 5
- SBP remains low or symptomatic despite initial therapy 5
- Renal function worsening with therapy 5
- Requiring parenteral vasoactive agents 5
- Being considered for advanced therapies (LVAD, transplant) 5
Class III (DO NOT USE): Routine invasive monitoring in normotensive patients responding to diuretics/vasodilators is NOT recommended. 5
8. Arrhythmia Management
Q: How do you manage new-onset atrial fibrillation in acute HF?
AF is present in >30% of acute HF admissions and requires rate control and anticoagulation. 2
Rate control:
- Beta-blockers (preferred if tolerated) 7
- Digoxin (if beta-blockers contraindicated or inadequate) 7
- Avoid non-dihydropyridine calcium channel blockers (verapamil, diltiazem) in HFrEF 1, 5
Rhythm control:
- Electrical cardioversion may be considered for persistent AF, especially if recent onset and left atrium not severely enlarged 7
- If antiarrhythmic therapy needed: amiodarone is the ONLY safe option in HF 7
Anticoagulation:
- Initiate based on CHA2DS2-VASc score (most HF patients qualify) 8
- Direct oral anticoagulants preferred over warfarin 8
9. Renal Dysfunction (Cardiorenal Syndrome)
Q: The creatinine is rising with diuresis—what do you do?
Mild worsening of renal function during decongestion is common and should NOT routinely prompt discontinuation of diuretics or GDMT. 4
Assess the clinical context:
- If patient is still congested: Continue aggressive diuresis—persistent congestion causes worse renal outcomes than transient creatinine elevation 4
- If patient is euvolemic: Consider reducing diuretic dose, but maintain GDMT 4
- If creatinine rising with hypotension: May indicate true hypoperfusion—consider reducing vasodilators, optimizing volume status 3
Worsening renal function is an indication for invasive hemodynamic monitoring if unclear whether due to congestion vs. hypoperfusion. 5
10. Discharge Planning & Readmission Prevention
Q: What must be done before discharge to prevent readmission?
The 30-day readmission rate is 25% and 6-month mortality is 25-35%—discharge planning is critical. 1, 9
Mandatory pre-discharge interventions:
Clinical optimization:
- Achieve euvolemia (no JVP elevation, minimal edema) 3
- Transition to oral diuretics with demonstrated efficacy 2
- Optimize GDMT to target or maximally tolerated doses 2, 4
- Ensure stable renal function and electrolytes 3
Patient education:
- Daily weights (call if gain >2-3 lbs in 1 day or 5 lbs in 1 week) 3
- Sodium restriction (<2-3 g/day) 1
- Fluid restriction if hyponatremic 1
- Medication adherence strategies 1, 4
- Recognition of worsening symptoms 3
Follow-up:
- Cardiology or HF clinic appointment within 7 days of discharge 3
- Consider multidisciplinary HF management program 7, 10
Medication reconciliation:
11. Red Flags for Readmission
Q: What findings predict high risk of readmission or death?
These factors identify patients needing intensive follow-up: 3
Fixed risk factors:
- Age >75 years 3
- Multiple prior HF hospitalizations 3
- Comorbidities: diabetes, COPD, chronic kidney disease, cancer, dementia 3, 8
- Frailty 3
Modifiable risk factors at discharge:
- Persistent congestion (elevated JVP, edema) 3
- Elevated natriuretic peptides (higher = worse prognosis) 3
- Worsening renal function 3
- Low systolic BP (<110 mmHg) 3
- Hyponatremia 3
- Suboptimal GDMT dosing 3, 4
- No outpatient follow-up arranged 3
Patients with multiple risk factors require enhanced transitional care, home health services, or HF disease management programs. 7, 10
12. Special Populations
Q: How does management differ in elderly patients (>80 years)?
Elderly patients have higher comorbidity burden, polypharmacy risks, and different HF phenotypes (more HFpEF). 7, 9
Key modifications:
- Medication titration: Start lower, titrate slower due to higher adverse event rates 7
- Orthostatic hypotension: Measure standing BP (not sitting) after 3-5 minutes—common cause of falls 7
- Cognitive assessment: Screen for delirium/dementia (affects self-care ability) 7, 10
- Frailty assessment: Impacts prognosis and treatment goals 3, 10
- Goals of care discussion: Address prognosis, advance directives, resuscitation preferences early 7
- Comprehensive geriatric assessment: May improve outcomes in frail elderly 7
Avoid therapeutic nihilism—elderly patients benefit from GDMT but require individualized dosing and close monitoring. 7
13. HFpEF vs HFrEF Management
Q: How does management differ for HFpEF (EF >40%)?
HFpEF accounts for ~50% of HF admissions, is more common in elderly, women, and those with hypertension. 7
Acute management is similar:
- Diuretics for congestion 7
- Blood pressure control (often severely hypertensive) 2, 7
- Identify and treat precipitants 7
Chronic management differs:
- SGLT2 inhibitors: Reduce HF hospitalizations (emerging evidence) 4
- Diuretics: Use cautiously—excessive diuresis reduces preload and cardiac output 7
- Beta-blockers: May improve symptoms by increasing diastolic filling time 7
- ACE-I/ARBs: Less robust mortality benefit than in HFrEF, but ARBs may reduce hospitalizations 7
- Avoid: Excessive diuresis, medications that reduce preload excessively 7
Focus on comorbidity management: Hypertension, diabetes, obesity, atrial fibrillation. 7, 8
14. Comorbidity-Specific Management
Q: How do you manage HF with significant comorbidities?
Comorbidities are present in >80% of HF patients and often precipitate decompensation. 1, 8
Diabetes mellitus (present in 30-40%): 8
- Metformin is safe in stable HF 8
- SGLT2 inhibitors reduce HF hospitalizations—preferred agent 4, 8
- Avoid thiazolidinediones (cause fluid retention) 2, 8
Chronic kidney disease (present in 45-63%): 8
- Adjust medication doses for GFR 8
- Monitor electrolytes closely (hyperkalemia risk with RAAS inhibitors) 8
- Persistent congestion worsens renal function more than transient creatinine elevation 4
COPD (present in 30-40%): 8
- Beta-blockers are underused but should NOT be withheld—use cardioselective agents (metoprolol, bisoprolol, carvedilol) 8
- Avoid non-selective beta-blockers 8
Anemia/iron deficiency: 8
Sleep apnea: 8
15. Advanced Therapies
Q: When do you consider advanced HF therapies?
Consider referral for advanced HF evaluation when: 5
Clinical criteria:
- Persistent NYHA Class III-IV symptoms despite optimal GDMT 5
- Recurrent hospitalizations 5
- Requiring continuous IV inotropes 5
- Progressive end-organ dysfunction (renal, hepatic) 5
- Cardiogenic shock 5
Hemodynamic criteria:
Advanced therapy options:
- Cardiac resynchronization therapy (CRT) if QRS ≥150 ms with LBBB 4
- Implantable cardioverter-defibrillator (ICD) for primary prevention if EF ≤35% 4
- Left ventricular assist device (LVAD) 5
- Heart transplantation 5
Early referral to advanced HF center improves outcomes—don't wait until multi-organ failure. 5